|
| | 
|
 | |
        
|  |
|  |
|
 Celgene Corporati - [Ticker: CELG] |     | | Última Transacción | 69,080 | Hora de Cotización | 2012-05-23 - 21:00 | | Variación | -0,570 (-0.82%) | Rango 52 Semanas | [51,700 - 80,420] | | Máximo | 69,380 | Mínimo | 68,400 | | Volumen | 2.533.841 | Volumen Medio (3m) | 2.975.630 | | Demanda / Oferta | 68,650 x 100 - 69,230 x 200 | Yield | N/A | | Cierre Anterior | 69,650 | PER | 21,68% | | Apertura | 69,295 | EPS | 3,21 | | Fecha Ex-Dividendo | N/A | Fecha Dividendo | N/A | | Capitalización Bursátil | 30 | Objetivo Estimado 1 Año | 84,280 | | Nota: Los datos pueden tener un retraso de algunos minutos. |
| | Ver cotizaciones de otros activos |
| Últimos 10 Tópicos en el Foro relacionados con Celgene Corporati: | | No se han encontrado tópicos relacionados con Celgene Corporati [CELG], pero se aconseja la búsqueda en el Foro para tópicos relacionados con Celgene Corporati. |
|
Noticias de Celgene Corporati [CELG]: (ordenadas por relevancia)
| |
Cinco vías para 'atacar' el sector de la biotecnologíaelEconomista.esEl caso más claro es el de Celgene (CELG.NQ), que mientras que se ha anotado un 4,6% desde el 1 de enero, ha visto caer su PER (veces que el beneficio está contenido en el precio) casi un 2%. Además, es una de las que cuenta con mayor potencial y es la ... |
|
The biggest R&D spenders in biotechFierceBiotechGilead ($GILD) bought its way into the hot race on hep C. Celgene ($CELG) has been aggressive on its own front, buying Avila and investing in new technology. And Vertex ($VRTX) showed that when you stay aggressive, and smart, you should never be ...y más » |
|
Zacks Reaffirms Neutral Rating on Celgene (CELG)Junction ReportCelgene (NASDAQ: CELG)'s stock had its ?neutral? rating reiterated by Zacks in a research note issued to investors on Friday. They currently have a $74.00 price target on the stock. Zacks' analyst wrote, ?Celgene's first quarter 2012 adjusted earnings ...y más » |
|
Celgene Retains Neutral RecZacks.comWe are maintaining our Neutral recommendation on Celgene Corporation (CELG - Analyst Report) with a target price of $74.00. Celgene disclosed its first quarter 2012 results last month. The company earned 96 cents on an adjusted basis during the quarter ...y más » |
|
Celgene Rating Lowered to Neutral at Bank of America (CELG)Daily PoliticalCelgene (NASDAQ: CELG) was downgraded by equities researchers at Bank of America (NYSE: BAC) from a ?buy? rating to a ?neutral? rating in a report issued on Friday. Shares of Celgene traded down 0.62% during mid-day trading on Friday, hitting $72.925.y más » |
|
Celgene Sets The Stage For Patient InvestorsSeeking AlphaBut Vertex isn't alone in offering shareholders a promising pipeline. Another recently beaten up stock, Celgene (CELG), also may reward patient shareholders. Celgene shares have retreated 13% since peaking a shade above $80 in early April.y más » |
|
4-Star Stocks Poised to Pop: CelgeneDailyFinanceBy Brian D. Pacampara, The Motley Fool Based on the aggregated intelligence of 180000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (NAS: CELG) has earned a respected four-star ...y más » |
| Para más noticias de Celgene Corporati hacer clic aquí:
Noticias de Celgene Corporati |
|
Anchura de la Página:
Imagen de Fondo: |
|  | |
|
|
![Gráfico de Celgene Corporati - [Ticker: CELG]](http://www.bolsaes.com/grafico/bolsaes-CELG-1-ano.png "Gráfico 1 Año de Celgene Corporati [CELG] BolsaES")
